Dr Reddy's Laboratories CEO: 'very positive outlook' for Indian pharma industry despite Trump 2.0
CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be supported by the Trump administration. A strong U.S. dollar is bolstering earnings growth.
Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ...
Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market expansions, despite facing price erosion and compliance challenges.
Hyderabad-based pharma major Dr Reddy’s Laboratories shares down 5% on Q3 earnings
Dr Reddy’s Laboratories on Thursday said its consolidated net profit increased 2 per cent to Rs 1,413 crore in the third quarter ended December 31, 2024. The Hyderabad-based drug major had reported a profit of Rs 1,379 crore for the October-December period of last fiscal.
Indian drugmaker Dr Reddy's shares slide after Q3 profit miss
(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine months, after missing its third-quarter profit estimates on lower sales and pricing pressures in the key North American market.
Dr Reddy's Laboratories Shares Plummet Despite Profit Increase
Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The stock closed lower on both BSE and NSE, wiping off a market valuation of Rs 5,399.
Dr. Reddy's Laboratories Q3 Results: Profit Rises 2%, But Misses Estimates
Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' estimates.
Dr Reddy's Shares Plunge 7% After Disappointing Q3 Earnings
Dr Reddy's Laboratories shares dropped nearly 7% on Friday after the company reported a slight increase in net profit for the third quarter, disappointing investors.
Dr Reddy’s shares plummet 4.4% in the wake of logging modest Q3 growth
Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.
Indian drugmaker Dr Reddy's misses Q3 profit view on weak pricing in US
BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American market,
Dr Reddy’s Q3 profit rises 2%
Hyderabad: Despite posting record revenues, pharma major Dr Reddy's Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at 1,
Dr. Reddy's Laboratories underperforms Friday when compared to competitors
Dr. Reddy's Laboratories Ltd. 500124 shares slid 5.01% to 1,224.70 Indian rupees Friday, on what proved to be an all-around ...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...
Reduce Dr. Reddy's Laboratories; target of Rs 1335: Prabhudas Lilladher
Prabhudas Lilladher recommended reduce rating on Dr. Reddy's Laboratories with a target price of Rs 1335 in its research ...
Dr. Reddy's Laboratories underperforms Thursday when compared to competitors
Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.54% to 1,289.35 Indian rupees Thursday, on what proved to be an all ...
Healthcare stocks rally over 2% as CLSA upgrades Dr Lal Pathlabs and Aurobindo; DRL drops on downgrade
Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...